98%
921
2 minutes
20
As important modulators of human purinergic signaling, P2X1 receptors form homotrimers to transport calcium, regulating multiple physiological processes, and are long regarded as promising therapeutic targets for male contraception and inflammation. However, the development of drugs that target the P2X1 receptor, such as the antagonist NF449, is greatly hindered by the unclear molecular mechanism of ligand binding modes and receptor activation. Here, we report the structures of the P2X1 receptor in complex with the endogenous agonist ATP or the competitive antagonist NF449. The P2X1 receptor displays distinct conformational features when bound to different types of compounds. Despite coupling to the agonist ATP, the receptor adopts a desensitized conformation that arrests the ions in the transmembrane (TM) domain, aligning with the nature of the high desensitization rates of the P2X1 receptor within the P2X family. Interestingly, the antagonist NF449 not only occupies the orthosteric pocket of ATP but also interacts with the dorsal fin, left flipper, and head domains, suggesting a unique binding mode to perform both orthosteric and allosteric mechanisms of NF449 inhibition. Intriguingly, a novel lipid binding site adjacent to the TM helices and lower body of P2X1, which is critical for receptor activation, is identified. Further functional assay results and structural alignments reveal the high conservation of this lipid binding site in P2X receptors, indicating important modulatory roles upon lipid binding. Taken together, these findings greatly increase our understanding of the ligand binding modes and multiple modulatory mechanisms of the P2X1 receptor and shed light on the further development of P2X1-selective antagonists.Keywords: Structural biology; Ligand binding mode; Ion channel; Purinergic P2X1 receptor.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373929 | PMC |
http://dx.doi.org/10.1038/s41401-025-01512-y | DOI Listing |
Am J Clin Exp Urol
April 2025
Department of Surgery, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School Boston, MA, USA.
Objectives: Extracellular ATP/ADP and its metabolite adenosine play crucial roles in cellular signaling by interacting with P2 and P1/adenosine receptors. These signaling molecules are regulated by ectonucleotidases, which convert ATP/ADP into adenosine. While recent studies suggest impaired ATP hydrolysis in the aging prostate, the expression and function of ectonucleotidases and purinergic receptors in the prostate gland remain unclear.
View Article and Find Full Text PDFBull Exp Biol Med
March 2025
Kazan State Medical University, Kazan, Russia.
At the neuromuscular junction, ATP and its metabolite adenosine regulate the release of acetylcholine by activating purinergic receptors (P2), thereby regulating the function of skeletal muscles under normal and pathological conditions. The presence of P2 receptors in the neuromuscular junction was assessed immunohistochemically on sections of m. soleus, m.
View Article and Find Full Text PDFPurinergic Signal
April 2025
School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, NG7 2UH, UK.
Hypochlorous acid (HOCl) is generated by neutrophils during the innate immune response. ATP is released from cells by various stimuli and during inflammation but whether ATP is released by and participates in the response to HOCl is unclear. This study investigated vasomotor effects of HOCl on the porcine coronary artery (PCA) and the involvement of ATP and purine receptors.
View Article and Find Full Text PDFActa Pharmacol Sin
September 2025
Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China.
As important modulators of human purinergic signaling, P2X1 receptors form homotrimers to transport calcium, regulating multiple physiological processes, and are long regarded as promising therapeutic targets for male contraception and inflammation. However, the development of drugs that target the P2X1 receptor, such as the antagonist NF449, is greatly hindered by the unclear molecular mechanism of ligand binding modes and receptor activation. Here, we report the structures of the P2X1 receptor in complex with the endogenous agonist ATP or the competitive antagonist NF449.
View Article and Find Full Text PDFInt J Mol Sci
March 2025
Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.
Purinergic P2 receptors are crucial in energy utilization and cellular signaling, making them key targets for stroke therapies. This study examines the temporal mRNA expression of all P2 receptors in rats and mice. Both species exhibited a common subset of P2X and P2Y receptors with elevated expression following cerebral ischemia and reperfusion (I/R), highlighting conserved mechanisms across these species.
View Article and Find Full Text PDF